|
US3031450A
(en)
*
|
1959-04-30 |
1962-04-24 |
Thomae Gmbh Dr K |
Substituted pyrimido-[5, 4-d]-pyrimidines
|
|
US3322755A
(en)
*
|
1964-03-10 |
1967-05-30 |
Boehringer Sohn Ingelheim |
Basic-substituted 1, 2, 3, 4-tetrahydropyrimido [5, 4-d]-pyrimidines
|
|
US3536809A
(en)
*
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
|
US3598123A
(en)
*
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US4162316A
(en)
*
|
1975-03-12 |
1979-07-24 |
Dainippon Pharmaceutical Co., Ltd. |
1-Substituted-4-(1,2-diphenylethyl)piperazine derivatives and compositions containing the same
|
|
US4008719A
(en)
*
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
|
US4001237A
(en)
*
|
1976-02-18 |
1977-01-04 |
Bristol-Myers Company |
Oxazole, isoxazole, thiazole and isothiazole amides
|
|
US4001238A
(en)
*
|
1976-02-18 |
1977-01-04 |
Bristol-Myers Company |
1,3,4-oxadiazole amides
|
|
US4047404A
(en)
*
|
1976-11-17 |
1977-09-13 |
Tanno Senshoku Kogyo Co., Ltd. |
Printed fabric washing apparatus
|
|
US4101548A
(en)
*
|
1977-02-22 |
1978-07-18 |
Bristol-Myers Company |
1,2,3-Thiadiazole amides
|
|
US4209623A
(en)
*
|
1978-06-07 |
1980-06-24 |
Bristol-Myers Company |
Pyrimidine-5-N-(1H-tetrazol-5-yl)-carboxamides
|
|
IE58110B1
(en)
*
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
|
US5391485A
(en)
*
|
1985-08-06 |
1995-02-21 |
Immunex Corporation |
DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
|
|
JPS63500636A
(ja)
*
|
1985-08-23 |
1988-03-10 |
麒麟麦酒株式会社 |
多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
|
|
US4810643A
(en)
*
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
|
ES2031513T3
(es)
*
|
1986-08-21 |
1992-12-16 |
Pfizer Inc. |
Quinazolindionas y piridopirimidinadionas.
|
|
GB8827988D0
(en)
*
|
1988-11-30 |
1989-01-05 |
Smith Kline French Lab |
Chemical compounds
|
|
IT1229203B
(it)
*
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
|
US5120548A
(en)
*
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
|
KR0166088B1
(ko)
*
|
1990-01-23 |
1999-01-15 |
. |
수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
|
|
US5733566A
(en)
*
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
|
WO1992014455A1
(en)
*
|
1991-02-14 |
1992-09-03 |
The Rockefeller University |
METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES
|
|
US5401774A
(en)
*
|
1991-03-08 |
1995-03-28 |
University Of Arizona |
Method for treating patients with precancerous lesions by administering substituted sulfonyl idenyl acetic and propionic acids and esters to patients with lesions sensitive to such compounds
|
|
US5580578A
(en)
*
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
|
US5354571A
(en)
*
|
1992-04-27 |
1994-10-11 |
Rheon Automatic Machinery Co., Ltd. |
Method for aligning and bending individual round elongated dough pieces
|
|
JP2657760B2
(ja)
*
|
1992-07-15 |
1997-09-24 |
小野薬品工業株式会社 |
４−アミノキナゾリン誘導体およびそれを含有する医薬品
|
|
US5360352A
(en)
*
|
1992-12-24 |
1994-11-01 |
The Whitaker Corporation |
Wire retainer for current mode coupler
|
|
US5591767A
(en)
*
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
|
US5629327A
(en)
*
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
|
US20010056114A1
(en)
*
|
2000-11-01 |
2001-12-27 |
D'amato Robert |
Methods for the inhibition of angiogenesis with 3-amino thalidomide
|
|
US6114355A
(en)
*
|
1993-03-01 |
2000-09-05 |
D'amato; Robert |
Methods and compositions for inhibition of angiogenesis
|
|
US6228879B1
(en)
*
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
|
US5698579A
(en)
*
|
1993-07-02 |
1997-12-16 |
Celgene Corporation |
Cyclic amides
|
|
US5614627A
(en)
*
|
1993-09-10 |
1997-03-25 |
Eisai Co., Ltd. |
Quinazoline compounds
|
|
IT1270594B
(it)
*
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
|
US5608914A
(en)
*
|
1994-11-21 |
1997-03-11 |
Keesler; Daren |
Headcover
|
|
GB9423910D0
(en)
*
|
1994-11-26 |
1995-01-11 |
Pfizer Ltd |
Therapeutic agents
|
|
US5801195A
(en)
*
|
1994-12-30 |
1998-09-01 |
Celgene Corporation |
Immunotherapeutic aryl amides
|
|
US5614530A
(en)
*
|
1995-03-10 |
1997-03-25 |
Sterling Winthrop Inc. |
Substituted N-arylmethyl and heterocyclmethyl-1H-pyrazolo[3,4-b]quinolin-4-amines and compositions and methods of use thereof
|
|
US5488055A
(en)
*
|
1995-03-10 |
1996-01-30 |
Sanofi Winthrop Inc. |
Substituted N-cycloalkylmethyl-1H-pyrazolo(3,4-b)quinolin-4 amines and compositions and methods of use thereof
|
|
ES2175079T3
(es)
*
|
1995-04-10 |
2002-11-16 |
Fujisawa Pharmaceutical Co |
Derivados de indol utiles como inhibidores de cgmp-pde.
|
|
US5731325A
(en)
*
|
1995-06-06 |
1998-03-24 |
Andrulis Pharmaceuticals Corp. |
Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
|
|
GB9514473D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Chemical compounds
|
|
US5728845A
(en)
*
|
1995-08-29 |
1998-03-17 |
Celgene Corporation |
Immunotherapeutic nitriles
|
|
US5728844A
(en)
*
|
1995-08-29 |
1998-03-17 |
Celgene Corporation |
Immunotherapeutic agents
|
|
US5658940A
(en)
*
|
1995-10-06 |
1997-08-19 |
Celgene Corporation |
Succinimide and maleimide cytokine inhibitors
|
|
US5710170A
(en)
*
|
1995-12-15 |
1998-01-20 |
Merck Frosst Canada, Inc. |
Tri-aryl ethane derivatives as PDE IV inhibitors
|
|
GB9526243D0
(en)
*
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9526246D0
(en)
*
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
DE19613976C1
(de)
*
|
1996-04-09 |
1997-11-20 |
Gruenenthal Gmbh |
Thalidomid-Prodrugs mit immunmodulatorischer Wirkung
|
|
US6281230B1
(en)
*
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
|
US5798368A
(en)
*
|
1996-08-22 |
1998-08-25 |
Celgene Corporation |
Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
|
|
HU228769B1
(en)
*
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
US5635517B1
(en)
*
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
|
RU2188819C2
(ru)
*
|
1996-08-12 |
2002-09-10 |
Селджин Корпорейшн |
НОВЫЕ ИММУНОТЕРАПЕВТИЧЕСКИЕ СОЕДИНЕНИЯ, СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СНИЖЕНИЯ УРОВНЕЙ ФДЭ, TNFα И NFκB
|
|
US6034089A
(en)
*
|
1997-10-03 |
2000-03-07 |
Merck & Co., Inc. |
Aryl thiophene derivatives as PDE IV inhibitors
|
|
US6020339A
(en)
*
|
1997-10-03 |
2000-02-01 |
Merck & Co., Inc. |
Aryl furan derivatives as PDE IV inhibitors
|
|
US5874448A
(en)
*
|
1997-11-18 |
1999-02-23 |
Celgene Corporation |
Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
|
|
US5955476A
(en)
*
|
1997-11-18 |
1999-09-21 |
Celgene Corporation |
Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
|
|
EP1064277B1
(en)
*
|
1998-03-16 |
2005-06-15 |
Celgene Corporation |
2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
|
|
US6020358A
(en)
*
|
1998-10-30 |
2000-02-01 |
Celgene Corporation |
Substituted phenethylsulfones and method of reducing TNFα levels
|
|
US20030013739A1
(en)
*
|
1998-12-23 |
2003-01-16 |
Pharmacia Corporation |
Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
|
|
US6025394A
(en)
*
|
1999-01-29 |
2000-02-15 |
Cell Pathways, Inc. |
Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
|
|
AU764005B2
(en)
*
|
1999-02-25 |
2003-08-07 |
Merck Frosst Canada & Co. |
PDE IV inhibiting compounds, compositions and methods of treatment
|
|
KR100672892B1
(ko)
*
|
1999-03-18 |
2007-01-23 |
셀진 코오퍼레이션 |
치환된 1-옥소- 및 1,3-디옥소이소인돌린스 및 염증성사이토킨 수치를 감소시키기 위한 약학적 조성물로서의이들의 사용
|
|
US6667316B1
(en)
*
|
1999-11-12 |
2003-12-23 |
Celgene Corporation |
Pharmaceutically active isoindoline derivatives
|
|
US7182953B2
(en)
*
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
|
MXPA02009665A
(es)
*
|
2000-03-31 |
2005-09-08 |
Celgene Corp |
Inhibicion de actividad de ciclooxigenasa-2.
|
|
BR0110877A
(pt)
*
|
2000-05-15 |
2003-03-11 |
Celgene Corp |
Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer
|
|
US6458810B1
(en)
*
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
|
US20020128228A1
(en)
*
|
2000-12-01 |
2002-09-12 |
Wen-Jen Hwu |
Compositions and methods for the treatment of cancer
|
|
US7091353B2
(en)
*
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
|
US20030045552A1
(en)
*
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
|
AU2002306596B2
(en)
*
|
2001-02-27 |
2008-01-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Analogs of thalidomide as potential angiogenesis inhibitors
|
|
WO2003014315A2
(en)
*
|
2001-08-06 |
2003-02-20 |
The Children's Medical Center Corporation |
Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
|
|
US6962940B2
(en)
*
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
|
US7968569B2
(en)
*
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
US20040087558A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
|
US20040091455A1
(en)
*
|
2002-10-31 |
2004-05-13 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
|
|
US7563810B2
(en)
*
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
|
EP1567154A4
(en)
*
|
2002-11-06 |
2006-05-31 |
Celgene Corp |
METHODS AND COMPOSITIONS USING CYTOKINE SELECTIVE INHIBITION DRUGS FOR TREATING AND CONTROLLING CANCERS AND OTHER DISEASES
|